Portola Pharmaceuticals Company Profile (NASDAQ:PTLA)

About Portola Pharmaceuticals (NASDAQ:PTLA)

Portola Pharmaceuticals logoPortola Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company's two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots. Its third product candidate is Cerdulatinib. The Company's Syk is a mediator of immune response in various types of immune cells. The Company has a program of selective Syk inhibitors, one of which is partnered with Ora Inc. Betrixaban is an oral once-daily inhibitor of Factor Xa in development for extended duration venous thromboembolism (VTE) prophylaxis in acute medically ill patients. Andexanet alfa is an orphan drug, which is a recombinant protein designed to reverse anticoagulant activity in patients treated with an fXa inhibitor.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:PTLA
  • CUSIP: N/A
  • Web: www.portola.com
Capitalization:
  • Market Cap: $3.76219 billion
  • Outstanding Shares: 57,020,000
Average Prices:
  • 50 Day Moving Avg: $51.06
  • 200 Day Moving Avg: $39.08
  • 52 Week Range: $15.68 - $67.10
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -27.95
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $32.37 million
  • Price / Sales: 116.21
  • Book Value: $2.84 per share
  • Price / Book: 23.23
Profitability:
  • EBIDTA: ($242,850,000.00)
  • Net Margins: -759.21%
  • Return on Equity: -106.68%
  • Return on Assets: -69.77%
Debt:
  • Debt-to-Equity Ratio: 0.60%
  • Current Ratio: 6.81%
  • Quick Ratio: 6.81%
Misc:
  • Average Volume: 999,241 shs.
  • Beta: 1.31
  • Short Ratio: 2.64
 
Frequently Asked Questions for Portola Pharmaceuticals (NASDAQ:PTLA)

What is Portola Pharmaceuticals' stock symbol?

Portola Pharmaceuticals trades on the NASDAQ under the ticker symbol "PTLA."

How were Portola Pharmaceuticals' earnings last quarter?

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) issued its earnings results on Monday, May, 8th. The company reported ($0.74) EPS for the quarter, beating the consensus estimate of ($1.20) by $0.46. The company earned $5.12 million during the quarter, compared to analysts' expectations of $4.21 million. Portola Pharmaceuticals had a negative net margin of 759.21% and a negative return on equity of 106.68%. The business's revenue for the quarter was down 37.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted ($1.15) EPS. View Portola Pharmaceuticals' Earnings History.

Where is Portola Pharmaceuticals' stock going? Where will Portola Pharmaceuticals' stock price be in 2017?

8 analysts have issued twelve-month target prices for Portola Pharmaceuticals' stock. Their predictions range from $27.00 to $80.00. On average, they anticipate Portola Pharmaceuticals' share price to reach $63.83 in the next year. View Analyst Ratings for Portola Pharmaceuticals.

What are analysts saying about Portola Pharmaceuticals stock?

Here are some recent quotes from research analysts about Portola Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Portola Pharmaceuticals, Inc. is a biopharmaceutical company .It focuses on the development and commercialization of therapeutics for thrombosis, other hematologic disorders and inflammation. Portola Pharmaceuticals, Inc. is headquartered in South San Francisco, California. " (7/18/2017)
  • 2. Cowen and Company analysts commented, "Portola hosted an investor event at the American College of Cardiology (ACC) annual meeting. Data from betrixaban's APEX Phase III and AndexXa's ANNEXA-4 Phase IV trials were discussed. Investors were keenly focused on examining the APEX clinical data ahead of betrixaban's June PDUFA. While risk remains, we think approval is more likely than not. We remain at Outperform." (3/20/2017)

Who are some of Portola Pharmaceuticals' key competitors?

Who are Portola Pharmaceuticals' key executives?

Portola Pharmaceuticals' management team includes the folowing people:

  • Hollings C. Renton III, IndependentChairman of the Board
  • William Lis, Chief Executive Officer, Director
  • Mardi C. Dier, Chief Financial Officer, Executive Vice President
  • John T. Curnutte M.D. Ph.D., Executive Vice President - Research & Development
  • Tao Fu, Executive Vice President, Chief Commercial and Business officer
  • Jeffrey W. Bird M.D. Ph.D., Independent Director
  • Laura A. Brege, Independent Director
  • Dennis M. Fenton Ph.D., Independent Director
  • Charles J. Homcy M.D., Independent Director
  • John H. Johnson, Independent Director

Who owns Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional investors include Strs Ohio (0.32%), Harvey Capital Management Inc. (0.26%), Fisher Asset Management LLC (0.08%), US Bancorp DE (0.07%), Rothschild Investment Corp IL (0.04%) and Russell Investments Group Ltd. (0.03%). Company insiders that own Portola Pharmaceuticals stock include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, Fullerton Management Pte Ltd, Jeffrey W Bird, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Institutional Ownership Trends for Portola Pharmaceuticals.

Who sold Portola Pharmaceuticals stock? Who is selling Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Harvey Capital Management Inc. and Strs Ohio. Company insiders that have sold Portola Pharmaceuticals stock in the last year include (Mauritius) Pte Ltd Maxwell, Charles J Homcy, John T Curnutte, Mardi Dier, Tao Fu and William Lis. View Insider Buying and Selling for Portola Pharmaceuticals.

Who bought Portola Pharmaceuticals stock? Who is buying Portola Pharmaceuticals stock?

Portola Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Russell Investments Group Ltd., Parametrica Management Ltd, Aperio Group LLC, Hartwell J M Limited Partnership, Rothschild Investment Corp IL and US Bancorp DE. Company insiders that have bought Portola Pharmaceuticals stock in the last two years include Fullerton Management Pte Ltd and Jeffrey W Bird. View Insider Buying and Selling for Portola Pharmaceuticals.

How do I buy Portola Pharmaceuticals stock?

Shares of Portola Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Portola Pharmaceuticals' stock price today?

One share of Portola Pharmaceuticals stock can currently be purchased for approximately $65.97.


MarketBeat Community Rating for Portola Pharmaceuticals (NASDAQ PTLA)
Community Ranking:  3.4 out of 5 (  )
Outperform Votes:  190 (Vote Outperform)
Underperform Votes:  90 (Vote Underperform)
Total Votes:  280
MarketBeat's community ratings are surveys of what our community members think about Portola Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Portola Pharmaceuticals (NASDAQ:PTLA) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.75)
Consensus Price Target: $63.83 (3.24% downside)

Analysts' Ratings History for Portola Pharmaceuticals (NASDAQ:PTLA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/24/2017Oppenheimer Holdings, Inc.Boost Price TargetOutperform$66.00 -> $80.00LowView Rating Details
6/26/2017Credit Suisse GroupReiterated RatingNeutral$39.00 -> $58.00MediumView Rating Details
6/26/2017Morgan StanleyBoost Price TargetOverweight$50.00 -> $70.00LowView Rating Details
6/26/2017Cowen and CompanyBoost Price TargetOutperform$45.00 -> $70.00HighView Rating Details
6/26/2017William BlairReiterated RatingOutperformHighView Rating Details
6/26/2017Citigroup Inc.Boost Price TargetBuy$51.00 -> $78.00MediumView Rating Details
2/24/2017CIBCUpgradeMarket Perform -> OutperformN/AView Rating Details
1/11/2017Goldman Sachs Group, Inc. (The)Reiterated RatingNeutral$22.00 -> $27.00N/AView Rating Details
(Data available from 7/26/2015 forward)

Earnings

Earnings History for Portola Pharmaceuticals (NASDAQ:PTLA)
Earnings by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
Earnings History by Quarter for Portola Pharmaceuticals (NASDAQ PTLA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($1.20)($0.74)$4.21 million$5.12 millionViewListenView Earnings Details
2/28/2017Q4 2016($1.12)($0.95)$3.98 million$13.70 millionViewListenView Earnings Details
11/7/2016Q3($1.10)($1.64)$4.10 million$9.30 millionViewListenView Earnings Details
8/9/2016Q216($1.20)($1.02)$4.38 million$4.23 millionViewListenView Earnings Details
5/5/2016Q1($1.06)($1.15)$7.91 million$8.30 millionViewListenView Earnings Details
2/26/2016Q415($1.12)($1.23)$2.43 million$4.40 millionViewListenView Earnings Details
8/4/2015Q215($1.07)($1.12)$2.30 million$2.39 millionViewListenView Earnings Details
5/6/2015Q115($1.09)($0.95)$2.60 million$2.36 millionViewListenView Earnings Details
3/2/2015Q414($0.90)($0.82)$2.40 million$2.41 millionViewListenView Earnings Details
11/10/2014Q314($0.92)($0.86)$2.73 million$2.40 millionViewListenView Earnings Details
8/6/2014Q214($0.79)($0.76)$2.44 million$2.42 billionViewListenView Earnings Details
5/12/2014Q114($0.72)($0.75)$1.81 million$2.40 millionViewListenView Earnings Details
2/27/2014Q4($0.57)($0.63)$2.17 million$2.10 millionViewListenView Earnings Details
8/15/2013($0.72)($1.47)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Portola Pharmaceuticals (NASDAQ:PTLA)
2017 EPS Consensus Estimate: ($5.30)
2018 EPS Consensus Estimate: ($3.55)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20172($1.30)($1.12)($1.21)
Q2 20172($1.24)($1.06)($1.15)
Q3 20172($1.70)($1.27)($1.49)
Q4 20172($1.52)($1.38)($1.45)
Q1 20181($1.23)($1.23)($1.23)
Q2 20181($1.04)($1.04)($1.04)
Q3 20181($0.74)($0.74)($0.74)
Q4 20181($0.54)($0.54)($0.54)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Portola Pharmaceuticals (NASDAQ:PTLA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Portola Pharmaceuticals (NASDAQ:PTLA)
Insider Ownership Percentage: 4.90%
Institutional Ownership Percentage: 84.97%
Insider Trades by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
Insider Trades by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/18/2017John T. CurnutteInsiderSell10,000$65.00$650,000.00View SEC Filing  
7/18/2017Tao FuEVPSell5,812$65.00$377,780.00View SEC Filing  
7/11/2017Mardi DierVPSell23,350$60.00$1,401,000.00View SEC Filing  
6/28/2017William LisCEOSell269,299$55.43$14,927,243.57View SEC Filing  
6/27/2017Mardi DierVPSell93,392$55.46$5,179,520.32View SEC Filing  
6/26/2017John T. CurnutteInsiderSell60,000$57.88$3,472,800.00View SEC Filing  
6/26/2017Tao FuEVPSell7,000$57.14$399,980.00View SEC Filing  
6/23/2017Charles J. HomcyDirectorSell120,803$53.06$6,409,807.18View SEC Filing  
6/1/2017(Mauritius) Pte Ltd MaxwellMajor ShareholderSell1,700,000$34.40$58,480,000.00View SEC Filing  
6/1/2017Jeffrey W BirdDirectorBuy119,442$31.85$3,804,227.70View SEC Filing  
4/11/2017William LisCEOSell6,750$36.06$243,405.00View SEC Filing  
4/10/2017Tao FuEVPSell1,097$36.97$40,556.09View SEC Filing  
3/15/2017Charles J. HomcyDirectorSell50,000$40.06$2,003,000.00View SEC Filing  
3/15/2017Mardi DierVPSell10,235$40.02$409,604.70View SEC Filing  
5/2/2016William LisCEOSell5,675$23.86$135,405.50View SEC Filing  
12/9/2015Fullerton Management Pte LtdMajor ShareholderBuy750,000$48.00$36,000,000.00View SEC Filing  
9/18/2015Charles J. HomcyDirectorSell40,067$56.25$2,253,768.75View SEC Filing  
9/18/2015Mardi DierCFOSell8,912$55.00$490,160.00View SEC Filing  
7/15/2015John T CurnutteEVPSell10,000$50.00$500,000.00View SEC Filing  
7/15/2015William LisCEOSell50,000$50.00$2,500,000.00View SEC Filing  
7/13/2015Charles J HomcyDirectorSell50,000$48.00$2,400,000.00View SEC Filing  
7/2/2015William LisCEOSell15,000$45.60$684,000.00View SEC Filing  
7/1/2015William LisCEOSell30,000$45.01$1,350,300.00View SEC Filing  
6/30/2015William LisCEOSell15,000$44.48$667,200.00View SEC Filing  
6/29/2015Charles J HomcyDirectorSell100,000$43.78$4,378,000.00View SEC Filing  
6/22/2015John T CurnutteEVPSell10,000$47.50$475,000.00View SEC Filing  
6/16/2015John T CurnutteEVPSell10,000$45.00$450,000.00View SEC Filing  
6/8/2015Mardi DierCFOSell16,119$43.00$693,117.00View SEC Filing  
5/29/2015John T CurnutteEVPSell10,000$42.50$425,000.00View SEC Filing  
5/28/2015John T CurnutteEVPSell10,000$40.30$403,000.00View SEC Filing  
5/27/2015Mardi DierCFOSell6,076$41.00$249,116.00View SEC Filing  
5/12/2015Mardi DierCFOSell13,290$37.88$503,425.20View SEC Filing  
5/11/2015Hollings RentonDirectorSell10,520$38.33$403,231.60View SEC Filing  
5/11/2015Mardi DierCFOSell13,674$38.21$522,483.54View SEC Filing  
4/30/2015William LisCEOSell45,000$35.60$1,602,000.00View SEC Filing  
2/23/2015Charles J HomcyDirectorSell20,000$40.00$800,000.00View SEC Filing  
2/23/2015John T CurnutteEVPSell10,000$40.00$400,000.00View SEC Filing  
2/23/2015Mardi DierCFOSell5,692$39.95$227,395.40View SEC Filing  
2/18/2015John T CurnutteEVPSell10,000$37.50$375,000.00View SEC Filing  
2/17/2015Charles J HomcyDirectorSell20,000$36.00$720,000.00View SEC Filing  
2/17/2015John T CurnutteEVPSell10,000$35.00$350,000.00View SEC Filing  
2/13/2015Charles J HomcyDirectorSell20,000$34.05$681,000.00View SEC Filing  
2/13/2015John T CurnutteEVPSell10,000$32.50$325,000.00View SEC Filing  
1/28/2015Charles J HomcyDirectorSell19,700$30.00$591,000.00View SEC Filing  
1/20/2015William LisCEOSell20,000$27.32$546,400.00View SEC Filing  
1/16/2015William LisCEOSell20,000$26.94$538,800.00View SEC Filing  
11/25/2014Mardi DierCFOSell1,118$28.23$31,561.14View SEC Filing  
11/20/2014William LisCEOSell40,000$26.95$1,078,000.00View SEC Filing  
11/17/2014William LisCEOSell30,000$26.69$800,700.00View SEC Filing  
10/8/2014(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy1,600,000$26.00$41,600,000.00View SEC Filing  
8/25/2014Mardi DierCFOSell5,000$26.26$131,300.00View SEC Filing  
7/25/2014Mardi DierCFOSell5,000$24.11$120,550.00View SEC Filing  
7/3/2014William LisCEOSell30,000$30.41$912,300.00View SEC Filing  
6/30/2014William LisCEOSell10,000$29.23$292,300.00View SEC Filing  
6/25/2014Mardi DierCFOSell5,000$28.52$142,600.00View SEC Filing  
6/18/2014John T CurnutteEVPSell30,000$28.33$849,900.00View SEC Filing  
6/18/2014Mardi DierCFOSell3,706$29.95$110,994.70View SEC Filing  
6/16/2014John T CurnutteEVPSell10,000$26.00$260,000.00View SEC Filing  
6/10/2014Nicholas GalakatosDirectorSell1,369$23.36$31,979.84View SEC Filing  
5/29/2014Mardi DierCFOSell5,000$23.00$115,000.00View SEC Filing  
5/27/2014William LisCEOSell30,000$20.83$624,900.00View SEC Filing  
5/21/2014William LisCEOSell10,000$19.87$198,700.00View SEC Filing  
5/16/2014Jean Jacques BienaimeDirectorSell1,000$22.03$22,030.00View SEC Filing  
4/25/2014Mardi DierCFOSell5,000$24.14$120,700.00View SEC Filing  
3/25/2014Mardi DierCFOSell5,000$25.69$128,450.00View SEC Filing  
10/22/2013Charles J HomcyDirectorSell95,962$23.75$2,279,097.50View SEC Filing  
5/28/2013(Mauritius) Pte Ltd MaxwellMajor ShareholderBuy700,000$14.50$10,150,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Portola Pharmaceuticals (NASDAQ:PTLA)
Latest Headlines for Portola Pharmaceuticals (NASDAQ:PTLA)
Source:
DateHeadline
americanbankingnews.com logoQ2 2017 EPS Estimates for Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Boosted by Analyst
www.americanbankingnews.com - July 26 at 8:36 AM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. to Post FY2020 Earnings of $4.99 Per Share, Oppenheimer Holdings Forecasts (NASDAQ:PTLA)
www.americanbankingnews.com - July 25 at 4:26 PM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Rating Increased to Buy at BidaskClub
www.americanbankingnews.com - July 24 at 9:04 PM
finance.yahoo.com logoCramer: Don't Risk It All on a Small Biotech Unless You're Willing to Lose It All
finance.yahoo.com - July 21 at 6:23 AM
americanbankingnews.com logoInsider Selling: Portola Pharmaceuticals, Inc. (PTLA) Insider Sells 10,000 Shares of Stock
www.americanbankingnews.com - July 20 at 7:45 PM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (NASDAQ:PTLA) EVP Tao Fu Sells 5,812 Shares
www.americanbankingnews.com - July 20 at 7:45 PM
americanbankingnews.com logo$2.42 Million in Sales Expected for Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) This Quarter
www.americanbankingnews.com - July 20 at 11:10 AM
americanbankingnews.com logo Analysts Anticipate Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) to Post -$1.20 EPS
www.americanbankingnews.com - July 18 at 6:28 PM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - July 18 at 9:11 AM
seekingalpha.com logoPortola Pharmaceuticals (PTLA) - Seeking Alpha
seekingalpha.com - July 14 at 7:39 AM
finance.yahoo.com logoIs It Time to Sell Portola?
finance.yahoo.com - July 14 at 7:39 AM
americanbankingnews.com logoInsider Selling: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) VP Sells 23,350 Shares of Stock
www.americanbankingnews.com - July 13 at 7:52 PM
finance.yahoo.com logoPortola's Hitting All-Time Highs: Here's Why the Stock Should Go Higher
finance.yahoo.com - July 13 at 8:16 AM
finance.yahoo.com logoHow Portola Is Looking to Change the Anticoagulant Game
finance.yahoo.com - July 12 at 7:11 AM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (NASDAQ:PTLA) Receives Average Recommendation of "Buy" from Analysts
www.americanbankingnews.com - July 11 at 6:48 PM
prnewswire.com logoDaily Technical Summary Reports on Biotech Stocks -- PTC Therapeutics, Portola Pharma, Regeneron Pharma, and ... - PR Newswire (press release)
www.prnewswire.com - July 11 at 6:53 AM
finance.yahoo.com logoWhat Was Behind Portola Pharmaceuticals' 45% Pop?
finance.yahoo.com - July 6 at 4:27 PM
finance.yahoo.com logoPortola Pharmaceuticals Announces Upcoming Data Presentations on Betrixaban and Andexanet Alfa at the International Society on Thrombosis and Haemostasis (ISTH) 2017 Scientific and Standardization Committee Meeting
finance.yahoo.com - July 6 at 8:11 AM
nasdaq.com logoPortola Pharmaceuticals Inc (PTLA) CEO William Lis Sold $14.9 million of Shares
www.nasdaq.com - July 1 at 6:44 AM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) CEO Sells $14,927,243.57 in Stock
www.americanbankingnews.com - June 29 at 10:28 PM
seekingalpha.com logoPortola Stock Expected To Retain Momentum With BevyxXa Commercial Launch - Seeking Alpha
seekingalpha.com - June 29 at 6:16 AM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Insider John T. Curnutte Sells 60,000 Shares
www.americanbankingnews.com - June 28 at 7:20 PM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) VP Sells $5,179,520.32 in Stock
www.americanbankingnews.com - June 28 at 7:20 PM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. Expected to Earn Q3 2017 Earnings of ($1.27) Per Share (PTLA)
www.americanbankingnews.com - June 28 at 7:48 AM
americanbankingnews.com logoOppenheimer Holdings Equities Analysts Cut Earnings Estimates for Portola Pharmaceuticals, Inc. (PTLA)
www.americanbankingnews.com - June 28 at 7:24 AM
americanbankingnews.com logoInsider Selling: Portola Pharmaceuticals, Inc. (PTLA) EVP Sells 7,000 Shares of Stock
www.americanbankingnews.com - June 27 at 7:51 PM
americanbankingnews.com logoInsider Selling: Portola Pharmaceuticals, Inc. (PTLA) Director Sells 120,803 Shares of Stock
www.americanbankingnews.com - June 27 at 7:28 PM
benzinga.com logoPortola Pharmaceuticals: Expect Additional Upside From Here - Benzinga
www.benzinga.com - June 27 at 7:34 AM
finance.yahoo.com logoToday's Research Reports on Stocks to Watch: Portola and AVEO
finance.yahoo.com - June 27 at 7:34 AM
finance.yahoo.com logoOppenheimer Boosts Price Target for Portola Pharmaceuticals Inc (PTLA) Following FDA Approval
finance.yahoo.com - June 27 at 7:34 AM
americanbankingnews.com logoPortola Pharmaceuticals Target of Unusually Large Options Trading (PTLA)
www.americanbankingnews.com - June 26 at 6:09 PM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Earns "Neutral" Rating from Credit Suisse Group
www.americanbankingnews.com - June 26 at 5:50 PM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Price Target Raised to $78.00 at Citigroup Inc.
www.americanbankingnews.com - June 26 at 12:16 PM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Price Target Increased to $66.00 by Analysts at Oppenheimer Holdings, Inc.
www.americanbankingnews.com - June 26 at 11:00 AM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) PT Raised to $70.00 at Morgan Stanley
www.americanbankingnews.com - June 26 at 10:27 AM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Given Outperform Rating at Cowen and Company
www.americanbankingnews.com - June 26 at 9:04 AM
americanbankingnews.com logoPortola Pharmaceuticals' (PTLA) Outperform Rating Reiterated at William Blair
www.americanbankingnews.com - June 26 at 8:34 AM
rttnews.com logoPortola Pharmaceuticals Inc. (PTLA) Surged To A New High After FDA Approval
www.rttnews.com - June 26 at 8:06 AM
americanbankingnews.com logo$2.42 Million in Sales Expected for Portola Pharmaceuticals, Inc. (PTLA) This Quarter
www.americanbankingnews.com - June 24 at 8:52 AM
fool.com logoWhy Synchronoss Technologies, AK Steel Holding, and Portola Pharmaceuticals Jumped Today - Motley Fool
www.fool.com - June 24 at 1:07 AM
marketwatch.com logoPortola Pharma stock skyrockets after FDA approves anticoagulant for high-risk patients - MarketWatch
www.marketwatch.com - June 24 at 1:07 AM
finance.yahoo.com logoU.S. FDA Approves Bevyxxa® (betrixaban) First and Only Anticoagulant for Hospital and Extended Duration Prevention of Venous Thromboembolism (VTE) in Acutely Ill Medical Patients
finance.yahoo.com - June 23 at 8:04 PM
finance.yahoo.com logoFDA approves Portola's blood-thinning drug
finance.yahoo.com - June 23 at 8:04 PM
finance.yahoo.com logoPortola Pharma stock skyrockets after FDA approves anticoagulant for high-risk patients
finance.yahoo.com - June 23 at 8:04 PM
finance.yahoo.com logoPortola shares soar after FDA approves clot preventing drug
finance.yahoo.com - June 23 at 8:04 PM
finance.yahoo.com logoPortola Pharmaceuticals Inc.'s Green Light Sends Its Stock Soaring as Much as 51%
finance.yahoo.com - June 23 at 8:04 PM
finance.yahoo.com logoWhy Synchronoss Technologies, AK Steel Holding, and Portola Pharmaceuticals Jumped Today
finance.yahoo.com - June 23 at 8:04 PM
americanbankingnews.com logoPortola Pharmaceuticals, Inc. (PTLA) Raised to "Hold" at BidaskClub
www.americanbankingnews.com - June 22 at 6:04 PM
americanbankingnews.com logo Brokerages Expect Portola Pharmaceuticals, Inc. (PTLA) Will Announce Earnings of -$1.19 Per Share
www.americanbankingnews.com - June 22 at 2:08 PM
finance.yahoo.com logoPortola Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : PTLA-US : June 21, 2017
finance.yahoo.com - June 22 at 8:58 AM

Social

Chart

Portola Pharmaceuticals (PTLA) Chart for Wednesday, July, 26, 2017

This page was last updated on 7/26/2017 by MarketBeat.com Staff